Drug Search Results
More Filters [+]

Small Molecule Inhibitor - Immoon Therapeutics

Alternative Names: Small Molecule Inhibitor - Immoon Therapeutics
Latest Update: None
Latest Update Note: None

Product Description

Immoon Therapeutics is a pre-clinical stage biotech company developing first-in-class small molecule inhibitors to treat autoimmune diseases and B-cell lymphomas. We are looking into the "root cause" of a problem and addressing the formation of pathologic antibodies in autoimmune diseases. (Sourced from: https://www.linkedin.com/company/immoon-therapeutics/about/)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Immoon Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Small Molecule Inhibitor - Immoon Therapeutics

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Autoimmune Disease Unspecified|Lymphoma, B-Cell

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title